Literature DB >> 890669

Lymphangiomyomatosis with chylous ascites: treatment with dietary fat restriction and medium chain triglycerides.

P R Calabrese, H D Frank, H L Taubin.   

Abstract

Lymphangiomyomyoma is a tumor of lymphatic channels and lymph nodes, clinically manifested by recurrent chylous pleural effusions and ascites. The disease is usually progressive and unresponsive to surgery, chemotherapy, or irradiation. A case of lymphangiomyomatosis in a 24-year-old woman who presented with chylous ascites is described. The patient was treated with dietary fat restriction supplemented with medium chain triglycerides and has remained free of recurrent effusions for 2 years.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 890669     DOI: 10.1002/1097-0142(197708)40:2<895::aid-cncr2820400245>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Case report: a rare case of chylous ascites from Mycobacterium avium intracellulare in a patient with AIDS: review of the literature.

Authors:  C Rollhauser; M Borum
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

2.  Lymphoma and chylous ascites.

Authors:  S Hufford; E Hu
Journal:  West J Med       Date:  1988-05

Review 3.  Lymphangioleiomyomatosis, chylous ascites, and diet.

Authors:  E Calvo; L Amarillas; M A Mateos; J L Orradre; G Gilsanz; J L Alvarez-Sala; D Espinos
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

4.  A case of gallbladder cancer manifesting chylous ascites and chylothorax.

Authors:  S Shiina; M Ohshima; H Fujino; H Muto; H Yasuda; T Kawabe; K Tagawa; T Unuma; K Ibukuro; Y Inoue
Journal:  Gastroenterol Jpn       Date:  1989-04

5.  Pancreatic cancer with chylous ascites demonstrated by lymphoscintigraphy: successful treatment with peritoneovenous shunting.

Authors:  Hidetaka Wagayama; Tsuyoshi Tanaka; Makoto Shimomura; Katsufumi Ogura; Katsuya Shiraki
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.